The approval of VYVDURA co-formulated with Halozyme's ENHANZE technology in Japan is a significant regulatory milestone that could lead to increased usage and sales, directly benefiting Halozyme through licensing or royalty revenues. Given the size of the Japanese market and the potential for expanded use in other indications, this approval is likely to have a positive short-term impact on Halozyme's stock price.